Following the in vitro screening and validation of MSC and AgRP’s roles, the continued observation of their abilities to upregulate proteasome activity in vivo in a transgenic AD mouse model reinforce the significant and potential therapeutic benefits that may arise through the applications of MSCs and AgRP in AD therapy. This evidence concerns the gene AGRP and Alzheimer disease.